BioMarin Pharmaceutical Inc.
BMRN
$52.88
$0.300.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.24B | 3.22B | 3.09B | 3.06B | 2.95B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.24B | 3.22B | 3.09B | 3.06B | 2.95B |
| Cost of Revenue | 1.58B | 1.52B | 1.48B | 1.30B | 1.31B |
| Gross Profit | 1.66B | 1.70B | 1.61B | 1.76B | 1.64B |
| SG&A Expenses | 1.07B | 1.03B | 973.42M | 958.48M | 989.24M |
| Depreciation & Amortization | 19.02M | 19.39M | 24.19M | 24.35M | 33.81M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.68B | 2.57B | 2.48B | 2.29B | 2.33B |
| Operating Income | 564.79M | 650.73M | 615.50M | 776.08M | 619.65M |
| Income Before Tax | 385.59M | 482.48M | 679.27M | 840.04M | 674.31M |
| Income Tax Expenses | 116.85M | 133.58M | 158.86M | 182.80M | 150.42M |
| Earnings from Continuing Operations | 268.74 | 348.90 | 520.42 | 657.24 | 523.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 268.74M | 348.90M | 520.42M | 657.24M | 523.88M |
| EBIT | 564.79M | 650.73M | 615.50M | 776.08M | 619.65M |
| EBITDA | 631.29M | 722.89M | 698.22M | 859.33M | 710.79M |
| EPS Basic | 1.40 | 1.82 | 2.72 | 3.44 | 2.75 |
| Normalized Basic EPS | 2.07 | 2.36 | 2.22 | 2.75 | 2.21 |
| EPS Diluted | 1.36 | 1.77 | 2.66 | 3.37 | 2.69 |
| Normalized Diluted EPS | 2.03 | 2.31 | 2.16 | 2.67 | 2.13 |
| Average Basic Shares Outstanding | 768.66M | 767.13M | 765.59M | 763.99M | 762.20M |
| Average Diluted Shares Outstanding | 779.02M | 777.82M | 782.18M | 787.29M | 790.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |